Literatura fachowa

Udostępniamy Państwu następujące opracowania literackie na temat Polyergi:

  1. Baier, J.E., Neumann, H.A., Taufighi-Chirazi, T., Gallati, H., Ricken, D. (1994): Thymopentin, Factor AF2, and Polyerga improve impaired mitogen induced interferon-g release of peripheral blood mononuclear cells derived from tumor patients. TumorDiagnostik&Therapie 15: 21-6.

  2. Berressem, P., Frech, S., Hartleb, M. (1995): Additional therapy with Polyerga(R) improve immune reactivity and quality of life in breast cancer patients during rehabilitation. TumorDiagnostik & Therapie 16: 45-48.

  3. Borghardt, JE., Rosien, B., Frech, S., Hartleb, M. (1995): Polyerga as a supportive therapy could improve quality of life in head and neck cancer patients during chemotherapy. Supportive Care in Cancer Vol. 3: 360.

  4. Borghardt JE, Rosien B, Görtelmeyer R, Lindemann S, Hartleb M, Klingmüller M (2000): Effects of a spleen peptide preparation as supportive therapy in inoperable head and neck cancer patients. Arzneimittelforschung Drug Research. In Press.

  5. Jurin, M. et al. (1996): Porcine splenic peptides (Polyerga(R) decrease the number of experimental lung metastases in mice. Clin Exp Metastasis 15, 55-60.

  6. Jurin, M. et al. (1997): Chemotherapy and spleen peptides preparation, SP-1, (Polyerga) in the treatment of experimental lung metastases of mammary carcinoma in mice. Croatian Medical Journal 38: 317-321.

  7. Klingmüller, M. (1999): Spleen Peptides activate natural killer cells. Erfahrungsheilkunde 12/1999: 756-759.

  8. Klose, G., Mertens, J. (1977): Long term results of post-operative treatment of carcinoma of the stomach with Polyerga(R). Therapie Woche 27: 5359-5361.

  9. Landgraf, G. (1992): Cancer Therapy in Daily Practice. Zeitschrift fuer Allgemeinmedizin 68: 764-7.

  10. Maar, K. (1998): Improvement of the General Condition of Tumor Patients. Erfahrungsheilkunde 47: 60-4.

  11. Ojeda, G., Diez-Orejas, R., Portoles, P., Ronda, M., Del Pozo, M.L., Feito, M.J., Hartleb, M., Rojo, J.M. (1994): Polyerga, a biological response modifier enhancing T-lymphocyte dependent responses. Res Exp Med 94: 261-7.

  12. Vassilev, M., Antnonov, K., Tcheocharov, P., Krastev, Z. (1996): Effects of Low Molecular Weight Glycoproteins in Chronic Hepatitis B. Hepato-Gastroenerology 43, 882 - 886.

  13. Veen, A. van't, Ruyter, H.A. de, Mouton, J.W., Hartleb, M., Lachmann, B. (1995): Pretreatment with spleen extracts enhances survival in influenza A infected mice. Forsch Komplementärmed 3, 218 - 221.

  14. Zarkovic N., Hartleb,M., Zarkovic K., Borovic S., Golubic J., Kalisnik T., Frech S., Klingmüller M., Loncaric I., Bosnjak B., Jurin M., Kuhlmey J. (1998): Spleen peptides (Polyerga) inhibit development of artificial lung metastases of murine mammary carcinoma and increase efficiency of chemotherapy in mice. Cancer Biotherapy & Radiopharmaceuticals 13: 25-32.

If you belong to the group of health care professionals you can receive our product information brochure that summarizes all important scientific informations in a clearly arranged way.